The Boston Scientific ENROUTE Recall: What TCAR Carotid Patients Need to Know

Carotid artery disease is a narrowing of the arteries in the neck that carry blood to the brain. When plaque builds up there, a piece can break loose and travel upward, blocking a vessel in the brain and causing a stroke. Doctors treat serious narrowing in a few ways. One is carotid endarterectomy, an open operation to clean out the artery. Another is transcarotid artery revascularization, known as TCAR.

TCAR uses a small incision just above the collarbone to reach the carotid artery directly. Before the surgeon opens or stents the narrowed section, the ENROUTE system temporarily reverses the direction of blood flow in that artery. The idea is that any plaque or clot knocked loose during the procedure gets swept backward, away from the brain, and captured in a filter rather than carried up into the skull. The system that creates that flow reversal is the ENROUTE Transcarotid Neuroprotection System, sold in two versions, the standard model and the model marketed as the Neuroprotection System Plus.

The device has a history worth stating plainly. It was developed by Silk Road Medical, which won FDA approval for the TCAR platform in 2015. Boston Scientific closed its acquisition of Silk Road Medical on September 17, 2024, for roughly 1.13 billion dollars, and folded the business into its Peripheral Interventions division. According to the companies, the Silk Road products are the only devices commercially available for the TCAR procedure. So a recall of this system is not a recall of one option among many. It touches the only tools cleared for this specific operation.

On July 9, 2026, Boston Scientific sent hospitals an Urgent Medical Device Removal notice. The reason, in the FDA's own words, was the potential for arterial sheath tip separation or partial tip separation during use. In plain terms, the tip of the sheath that sits inside the artery can break off, in whole or in part, while the device is being used inside a patient.

The FDA classified the action as a Class I recall, the agency's most serious category, reserved for problems it believes can cause serious injury or death. The classification was posted in August 2026. Federal records list the recall under event number 99454, covering the ENROUTE Transcarotid Neuroprotection System and the ENROUTE Transcarotid Neuroprotection System Plus, recall numbers Z-2977-2026 and Z-2978-2026. The affected products carry material numbers SR-200-NPS and SR-250-NPS.

This was a removal, not a correction. That distinction matters, and it separates this recall from some others this firm has written about. Our article on the Abiomed Impella heart pump recalls describes actions the FDA classified as Class I that were framed as corrections, meaning the manufacturer updated the instructions and hospitals kept using the devices. Here Boston Scientific asked hospitals to stop using the affected product, segregate it, and return it. That is a stronger step.

On the scale of the recall, the government records point to a large footprint. FDA and openFDA records describe more than 115,000 units tied to the recall, distributed across the United States and to Australia, Canada, China, and Jamaica. On the question of harm, the record as reported is measured, and the company's position deserves to be stated as it stands: as of the July 9 notice, the FDA reported one serious injury and no deaths connected to the problem. That number reflects what had been reported at that point, not a ceiling on what a review of individual cases might find.

The danger of this failure is not abstract. When the sheath tip separates inside a carotid artery, the piece left behind has to go somewhere. The FDA's recall notice lists the consequences directly. A separated or partially separated tip may require an endovascular or surgical procedure to retrieve the retained piece, which means a second intervention on an artery that leads to the brain.

The FDA also lists the complications that can follow. They include embolism, where a fragment or clot blocks a vessel; stroke; transient ischemic attack, sometimes called a mini stroke; restenosis, a renarrowing of the treated artery; and thrombosis, the formation of a clot. These are the words the agency used, not our characterization. They describe exactly the kind of harm that TCAR is supposed to prevent, arriving instead as a result of the device meant to prevent it.

That irony is the heart of why these cases deserve a careful look. A patient goes in for a procedure whose entire purpose is to stop a stroke. If a stroke or a vascular injury follows, the natural assumption is that the underlying disease was simply worse than expected. The recall raises a different possibility that a family may never have been told about. Whether the device played a role in a specific case is a question that can only be answered by reading the operative record against the recall timeline.

A recall does not pay anyone, and it does not by itself prove that any particular patient was harmed. It is a manufacturer's acknowledgment, sometimes a reluctant one, that a product carries a risk serious enough for the government to act. The legal claim comes later, when a patient or family can show that the device failed, or was used improperly, and caused harm that otherwise would not have happened.

The honest complication in TCAR cases is that these patients already have serious carotid disease. Some strokes happen despite flawless care, because the underlying condition is dangerous on its own. That does not end the inquiry. It sharpens it. The question a case turns on is whether a specific harm traces to a device failure, such as a separated sheath tip and the retrieval or embolic event that followed, rather than to the disease that brought the patient to the operating room.

The patterns worth looking for in a medical record are concrete. A note that part of a device or sheath separated, broke, or could not be removed during a TCAR procedure. A second, unplanned procedure to retrieve a retained piece from the artery. A stroke, transient ischemic attack, or new neurological deficit that appeared during or shortly after a carotid procedure. Signs of a clot or a renarrowing of the treated artery in the weeks that followed. If one of those appears in your timeline, the connection to the device may never have been explained to you. That is common, and it is what a case review is for.

Claims involving the ENROUTE system can run on two tracks. A product liability claim targets the manufacturer, here Boston Scientific, on theories of design defect, manufacturing defect, or failure to warn. A recall for sheath tip separation is the kind of problem those theories are built to address, though a recall is a starting point for investigation, not a finished verdict against anyone.

A medical malpractice claim targets the doctor or hospital. In a carotid case that might involve improper technique, failure to recognize that a device had separated, failure to retrieve a retained fragment promptly, or inadequate response to signs of a stroke during the procedure. The two tracks can overlap in a single case, and which theory fits depends on the facts in the records. Our article on choosing a medical malpractice attorney explains why matching the theory to the proof matters as much as the sympathy in a case.

These device cases generally proceed individually, each on its own facts and its own medical record, rather than through a single consolidated proceeding. That makes documentation decisive. The operative note, the device labeling and lot information, the imaging, and the recall timeline have to be read together. It is the same lesson from our Defective Medical Devices coverage of the Medtronic HVAD recall and the Mazor X surgical robot, where the truth lived in more than one record at once.

One path matters for veterans and military families. If the procedure happened at a VA medical center or another federal facility, a claim about the medical care proceeds under the Federal Tort Claims Act, with its own strict administrative deadline, while any product claim against the manufacturer proceeds separately. Our FTCA article walks through how those government cases work and why the two tracks can run at the same time.

The deadlines are unforgiving, and they are already running. Virginia generally allows two years from the date of injury or death for personal injury, wrongful death, and product liability claims. The District of Columbia generally allows three years, and Maryland generally allows three years with an outer cap. A claim tied to care at a federal facility runs under the FTCA's two-year administrative clock, which starts before any lawsuit is filed. These are general rules, and the exact deadline for a specific case depends on facts an attorney has to check.

The discovery rule can change when the clock starts if the link between the device and the harm was not reasonably apparent at the time. In carotid cases that link is often invisible to a patient. A stroke after a TCAR procedure gets attributed to the artery disease, and no one mentions a device recall the patient never heard about. Whether the discovery rule rescues a particular claim is a case-specific question that should be answered by a lawyer, not assumed in either direction. Our article on the statute of limitations for medical malpractice explains how these clocks work in more detail.

The practical advice is simple. Waiting is the expensive mistake. Evidence gets harder to gather, memories fade, and deadlines pass while a patient assumes nothing can be done. The clock is already running, and the only way to learn where you stand is to ask now, while the answer can still help. A case review costs nothing, and the deadline question is usually the first thing we work out.

National Malpractice Lawyers represents patients and families in claims involving defective medical devices and the medical negligence that can accompany their use. This is our Defective Medical Devices practice area, the same one that covers our Abiomed Impella, Medtronic HVAD, and Mazor X surgical robot coverage. In device cases the truth usually sits in more than one record at once: the medical chart, the device and lot data, and the recall timeline. We read them together.

If you or a family member had a TCAR carotid procedure and suffered a stroke, a transient ischemic attack, a retained device fragment, an unplanned second procedure, or a vascular injury that may connect to the ENROUTE system, contact us for a confidential case review. Peter Anderson reads these inquiries personally. There is no fee unless we recover for you.